A 52-week double-blind study of the effect of rosiglitazone on cardiovascular structure and function in subjects with type 2 diabetes mellitus and congestive heart failure (NYHA class I/II)
Heart failure, Congestive
Phase 3
A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013